Pulmonary Arterial Hypertension (PAH)
Part of Cardiovascular Disease
🏥2Companies
❤️1Engagements
Companies in Pulmonary Arterial Hypertension (PAH)
Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.
Acceleron
Cambridge, Massachusetts, United States
Acceleron was a biopharmaceutical therapies company acquired by Merck in 2021.
Business ModelB2B, focused on discovery, development, and commercialization of biotherapeutics, generating revenue through collaboration, licensing, and research arrangements with partners like Celgene (now Bristol Myers Squibb).
Core TechExploiting the therapeutic potential of the transforming ...
Funding$493.0M
Founded2003
Drug Discovery/Development
59
Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.
Schrödinger
New York, New York, USA
Schrödinger is an international scientific software and biotechnology company, founded in 1990, developing computational tools for drug discovery and materials science. Its phys...
...moreBusiness ModelB2B (Software licensing) and a drug discovery model, advancing preclinical and clinical programs internally and through collaborations. SaaS is implied through platform licensing.
Core Techphysics-based computational platform
Funding$394.2M
Founded1990
Drug Discovery/Development
57